Press Releases

2015

December 21, 2015 Aduro Biotech Announces Initiation of Phase 1 Study of ADU-741 for the Treatment of Prostate Cancer


December 16, 2015 Aduro Biotech Receives Milestone Payment From Janssen for Acceptance of Investigational New Drug Application for ADU-741 in Prostate Cancer


December 14, 2015 Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 and GVAX Pancreas for the Treatment of Pancreatic Cancer


December 10, 2015 Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-214 for the Treatment of Lung Cancer


December 02, 2015 Aduro Biotech to Present at Oppenheimer Healthcare Conference


November 27, 2015 Aduro Biotech to Present at NASDAQ Investor Conference


November 24, 2015 Aduro Biotech Confirms All Clinical Trials Continue Unaltered and as Planned


November 23, 2015 Aduro Biotech Receives Orphan Drug Designation in the European Union for CRS-207 for the Treatment of Mesothelioma


November 23, 2015 Aduro Biotech Announces Third Quarter 2015 Financial Results


November 20, 2015 Aduro Biotech Europe's Chief Scientific Officer, Andrea Van Elsas, Ph.D. Featured as Keynote Speaker on Immunomodulatory Antibodies at ESMO Symposium on Immuno-Oncology 2015


November 20, 2015 Aduro Biotech Europe’s Chief Scientific Officer, Andrea Van Elsas, Ph.D. Featured as Keynote Speaker on Immunomodulatory Antibodies at ESMO Symposium on Immuno-Oncology 2015


November 19, 2015 Aduro Biotech Establishes European Subsidiary


November 18, 2015 Aduro Biotech Receives Milestone Payment From Janssen for Submission of Investigational New Drug Application for ADU-741 in Prostate Cancer


November 09, 2015 Aduro Biotech Announces Five Poster Presentations at the Society of Immunotherapy of Cancer Annual Meeting


November 04, 2015 Aduro Biotech to Present at Credit Suisse Healthcare Conference


October 29, 2015 Aduro Biotech Receives Milestone Payment From Janssen for Acceptance of Investigational New Drug Application for ADU-214 in Lung Cancer


October 28, 2015 Aduro Biotech and Protein Potential Present Data Demonstrating Novel Vaccine Offers 100% Protection in Malarial Model


October 08, 2015 Aduro Biotech Receives Milestone Payment From Janssen for Submission of Investigational New Drug Application for ADU-214 in Lung Cancer


September 26, 2015 Aduro Biotech Announces Phase 1b Mesothelioma Trial Featured in Spotlight Poster at ESMO/ECC


September 25, 2015 Met de overname van BioNovion versterkt Aduro Biotech haar belangrijke antilichaam-portfolio en -onderzoekcapaciteit.


September 24, 2015 Aduro Biotech Enters Into Definitive Agreement to Acquire Premier Antibody Portfolio and Engineering Capabilities Through Purchase of BioNovion


September 23, 2015 Aduro Biotech to Participate in Leerink Partners Immuno-Oncology Roundtable


September 21, 2015 Aduro Biotech Appoints Blaine Templeman as Executive Vice President, General Counsel and Secretary


September 09, 2015 Aduro Biotech Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies for the Treatment of Ovarian Cancer


September 08, 2015 Aduro Biotech Completes Enrollment in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer


September 02, 2015 Aduro Biotech to Present at BioCentury's NewsMakers in the Biotech Industry Conference


August 10, 2015 Aduro Biotech Announces Second Quarter 2015 Financial Results


August 10, 2015 Aduro Biotech Completes Enrollment in Phase 1b Clinical Trial of CRS-207 Immunotherapy for the Treatment of Mesothelioma


August 06, 2015 Aduro Biotech to Present at the 35th Annual Canaccord Genuity Growth Conference


June 29, 2015 Aduro Biotech Announces Immunotherapy Regimen Successfully Passes Futility Analysis in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer


June 26, 2015 Aduro Biotech Appoints Industry Veteran, Stephen Sherwin, M.D., to Its Board of Directors


June 02, 2015 Aduro Biotech Appoints Liana Wu as Vice President of Commercial


June 01, 2015 Aduro Biotech Announces ASCO Presentation of Encouraging Data From Ongoing Phase 1b Clinical Trial of Its Immunotherapy for the Treatment of Mesothelioma


May 28, 2015 Aduro Biotech Announces First Quarter 2015 Financial Results


May 07, 2015 Aduro Biotech's Preclinical Results for Its STING-Targeted CDN Immuno-Oncology Platform Highlighted in Prestigious Peer-Reviewed Publications


May 06, 2015 Aduro Biotech to Present at Bank of America Merrill Lynch 2015 Health Care Conference


April 20, 2015 Aduro Biotech Announces Close of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Concurrent Private Placement


April 14, 2015 Aduro Biotech Announces Pricing of Its Initial Public Offering


March 30, 2015 Aduro Biotech Establishes Major Collaboration with Novartis for Global Research, Development and Commercialization of Immuno-Oncology Products Derived from its Proprietary STING-Targeted CDN Platform Technology


March 26, 2015 Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma


February 26, 2015 Aduro Biotech Collaborates with Leaders in Cancer Research on Investigator-Sponsored Phase 2 Trial Combining Aduro’s Innovative Immunotherapies with Anti-PD-1 Technology to Treat Patients with Advanced Pancreatic Cancer


February 11, 2015 Aduro appoints Sylvia R. Wheeler as senior vice president, corporate affairs and investor relations


February 09, 2015 Aduro meets development milestone in immuno-oncology collaboration with Janssen for treatment of prostate cancer


January 20, 2015 Aduro Biotech reports long-term survival and immune biomarker data from Phase 2 clinical trial of its immuno-oncology regimen in patients with pancreatic cancer


January 12, 2015 Aduro Biotech announces Phase 2 clinical trial results for pancreatic cancer combination immunotherapy published in Journal of Clinical Oncology


January 05, 2015 Aduro Biotech closes $51.4 million Series D financing